Drug General Information (ID: DDIR2NHFYE)
Drug Name			Salmon calcitonin		Drug Info		Lithium carbonate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiosteporotic Agents				Antimanic Agents
Structure

Mechanism of Salmon calcitonin-Lithium carbonate Interaction (Severity Level: Moderate)
Increased renal excretion (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Salmon calcitonin				Lithium carbonate
Mechanism		Increase the excretion rate of lithium				Lithium salt
Key Mechanism Factor 1
		Factor Name		Pharmacokinetics
		Factor Description		Alters the excretion of the drug, resulting in changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Increased renal excretion of Lithium carbonate caused by Salmon calcitonin

Recommended Action
Management		Lithium levels should be measured frequently and dosage adjustments made accordingly if these drugs are given concurrently. Patients should be advised to notify their physician if they experience drowsiness, dizziness, weakness, ataxia, vomiting, diarrhea, thirst, blurry vision, or increased urination.

References
1	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
2	Passiu G, Bocchetta A, Martinelli V, Garau P, Del Zompo M, Mathieu A "Calcitonin decreases lithium plasma levels in man. Preliminary report." Int J Clin Pharm Res 18 (1998): 179-81. [PMID: 10052028]
3	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.